Tecentriq

What it is used for

Non-small cell lung cancer:,Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.,Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for first-line treatment of patients with metastatic non-squamous NSCLC who do not have tumour EGFR or ALK genomic aberrations.,Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.,Small cell lung cancer:,Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).,Urothelial carcinoma:,Tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who,- are considered cisplatin ineligible and whose tumours express PD-L1 (PD-L1 stained tumour- infiltrating immune cells [IC] covering greater than or equal to 5% of the tumour area), as determined by a validated test, or,- are considered ineligible for any other platinum-containing chemotherapy regardless of the level of tumour PD-L1 expression.,This indication is approved based on overall response rate and duration of response in a single-arm study. Improvements in overall survival, progression-free survival, or health-related quality of life have not been established.,Triple-negative breast cancer,Tecentriq, in combination with paclitaxel protein-bound, is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering greater than or equal to 1% of the tumour), as determined by a validated test and who have not received prior chemotherapy for metastatic disease. This indication is approved under provisional approval based on progression free survival. Continued approval for this indication depends on verification and description of clinical benefit in a confirmatory trial(s).